Jump to Main Content
Perinatal immunoprophylaxis in babies born to hepatitis B virus-positive mothers in Queensland Australia: A data linkage study
- Shen, Eddie X., Lambert, Stephen B., Malo, Jonathan A., Bennett, Sonya, Sheridan, Sarah L., Vasant, Bhakti R., Ware, Robert S.
- Vaccine 2019 v.37 no.22 pp. 2884-2888
- Hepatitis B virus, data collection, hepatitis B, immunoglobulins, infants, mothers, vaccination, vaccines, Queensland
- Vertical transmission from mother-to-child is an important mode of hepatitis B virus (HBV) infection, accounting for up to half of all incident cases globally. We evaluated the uptake of HBV neonatal vaccination and immunoglobulin delivery in Queensland, Australia, between 2001 and 2013. We identified HBV-positive mothers using linked notifiable conditions, hospitalisation, and perinatal administrative data. Perinatal receipt of monovalent HBV vaccine and hepatitis B immunoglobulin were examined. Of 710,859 live births, with 5753 infants (0.81%) born to identified HBV-positive mothers; 91.7% received HBV neonatal vaccine. Immunoglobulin uptake was 20.0% in 2012 and 36.6% in 2013. Uptake was higher when the mother’s HBV-positive status was recorded in perinatal records (69.6% if maternal HBV status recorded on perinatal data collection vs 9.5% otherwise). Delivery of neonatal HBV vaccination in Queensland was high. Improved identification and documentation of HBV-positive mothers’ status during the antenatal period was associated with increased immunoglobulin administration.